HyperRHO®

HyperRHO®S/D Full Dose is recommended for the prevention of Rh hemolytic disease of the newborn by its administration to the Rho(D) negative mother within 72 hours after birth of an?Rho(D) positive infant, providing that the criteria detailed in the package insert are met.

For full indications, dosing and other information, please refer to the prescribing information.

HyperRHO® ‐ Grifols

Size:
1500 IU, Single Dose Syringe
NDC #:
13533-0631-02
Download:
PI
Size:
1500 IU, 10 Pack, Single Dose Syringes
NDC #:
13533-0631-10
Download:
PI